Liaison(s): Bonnie Anderson
Veracyte is a private molecular diagnostics company committed to clarifying cancer diagnoses. The company’s goal is to use molecular cytology to develop diagnostic tools that may help physicians and patients make informed treatment decisions. The company is developing diagnostic tools intended to reduce the high rate of inconclusive test results associated with currently available technologies using fine needle aspirates (FNAs) and other cytology samples. This is the second TMP that Veracyte has sponsored. This year’s TMP was divided into two independent projects. In the fall semester the team focused on the development of a detailed commercialization strategy and Roll-out plan for Veracyte’s first commercial product in the US. The research gathered by the team was used to develop a strategic map showcasing regions with high probability of success and additionally proposed a long-term strategy. The second semester project involved the characterization of new market opportunities for a different indication. The team validated current diagnostic methods to evaluate the proposed clinical and economic models through secondary and primary research. Interviews with key opinion leaders provided the team with robust data which resulted in the validation of the clinical model for the targeted disease area.